Cutaneous amyloidosis as the first presentation of Waldenstrom macroglobulinemia

Proteomic analysis of waldenstrom macroglobulinemia.

To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family protein...

Waldenstrom macroglobulinemia: prognosis and management

Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells. Asymptomatic patients can be observed without therapy. First-line therapy should consist of the monoclonal anti-CD20 antibody, rituximab, given typically in combination with other agents. We pref...

Novel agents in Waldenstrom Macroglobulinemia.

Waldenström's Macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of the bone marrow (BM) with lymphoplasmacytic cells, as well as detection of an IgM monoclonal gammopathy in the serum. WM is considered an incurable disease, with an overall median survival of only 5-6 years. The success of targeted therapy in multiple myeloma (MM) has led to the development and invest...

Targeting NF-κB in Waldenstrom Macroglobulinemia

Intracardiac emboli as first presentation of cardiac AL amyloidosis.

Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;123:1061–1072. 14. Fang F, Chan JY, Yip GW, Xie JM, Zhang Q, Fung J...

Transgenic Mouse Models of Macroglobulinemia Waldenstrom

Pts were treated with 4 courses of 2-CDA (0.1 mg/kg sc for 5 days) in combination with Rituximab at standard schedule. Relative quantitation was performed using the Delta CT calculation: the value of gene expression was normalised to the calibrator (healthy tissue cells). Results. Clinical responses were evaluated according to Response Criteria (3 International Workshops on WM) 2 months after t...